Enveloped viruses such as HIV-1 and influenza A cloak their surface glycoproteins with dense arrays of host-derived N-linked glycans - the glycan shield - that physically mask conserved antibody epitopes. Structural work defined a taxonomy for HIV-1 Env in which 'crowded' glycans (15 or more neighboring sequons within a 50 Å radius) differ from 'dispersed' glycans in ordering, conservation, processing, and antibody recognition, and explicitly left open whether these characteristics are conserved in other viruses' shields. A separate sequence/structure analysis associated more complete glycan shields at HIV-1 transmission with later development of neutralization breadth, while admitting that its mapping assumed full glycan occupancy, ignored site-specific glycoform heterogeneity, and treated glycan dynamics only through a fixed 10 Å shielding radius. This problem asks for quantitative rules by which glycan occupancy, site-specific glycoform heterogeneity, and glycan dynamics jointly determine shield completeness and its immunological consequences (neutralization sensitivity and breadth) for HIV-1 Env, replacing those approximations and not restricted to any single glycan site or antibody class, and for a determination of whether the crowded-versus-dispersed taxonomy and its biological correlates generalize to influenza and other viruses. Substantial component progress exists - machine-learning occupancy-antigenicity models, atomistic shield-topology metrics, glycan-conformer simulation tools, cross-virus glycan-density comparisons - but no rule-level result jointly incorporates occupancy, glycoform heterogeneity, and dynamics, the completeness-breadth association was not replicated in larger cohorts, and no work has applied the crowded/dispersed taxonomy to any non-HIV virus. Both cores remain open.

Background

The surface glycoproteins of enveloped viruses are studded with N-linked glycans: sugar chains covalently attached to asparagine residues in sequon motifs (N-X-S/T), here called potential N-linked glycosylation sites (PNGS). Because these glycans are synthesized by host enzymes, the immune system tolerates them poorly as targets, yet they physically cover the conserved protein surface beneath; this 'glycan shield' is a shared immune-evasion strategy of HIV-1 and influenza, noted in reviews since at least 2007 (Vigerust and Shepherd, 2007). Three properties of the shield matter here. First, occupancy: a given PNGS may be glycosylated or not, and occupancy varies across sites and viruses. Second, glycoform heterogeneity: an occupied site can carry different glycan structures - under-processed oligomannose-type or fully processed complex-type sugars - so each site holds a distribution of glycoforms rather than a single structure. Third, glycan dynamics: glycans are flexible and sweep out volumes on nanosecond-to-microsecond timescales, so the shield is a moving ensemble rather than a static coat. 'Neutralization breadth' denotes the capacity of antibodies to neutralize genetically diverse viral strains (HIV-1 isolates are graded tier 1-3 by neutralization sensitivity); breaches in the shield, called glycan holes, are strain-specific targets. Crystal structures of fully glycosylated HIV-1 Env trimers (the gp120/gp41 envelope glycoprotein) from clades A, B, and G (the major genetic subtypes of the global HIV-1 pandemic) at 3.4-3.7 Å resolution revealed the shield as a network of interlocking oligosaccharides ordered by crowding, and defined a taxonomy: a glycan is 'crowded' if 15 or more neighboring sequons lie within a 50 Å radius, otherwise 'dispersed'; crowded and dispersed glycans differ in how ordered they are, how conserved their sites are, how processed their glycoforms are, and how antibodies recognize them (Stewart-Jones et al., Cell 2016). That paper closes by asking whether these biological characteristics are conserved in the glycan shields of other viruses. A later sequence- and structure-based analysis mapped glycan holes for individual Env sequences by assuming every PNGS occupied and shielding a fixed 10 Å radius around each glycan-bearing asparagine, and found that transmitted/founder viruses (the viral genomes that establish a new infection) with more complete shields developed greater neutralization breadth in 12 longitudinally followed individuals; the authors explicitly cautioned that the approach does not account for variable glycan occupancy or glycoform heterogeneity and approximates glycan dynamics only through that fixed shielding radius, noting glycans can extend roughly 20 Å perpendicularly from the protein surface (Wagh et al., Cell Reports 2018). On the influenza side, the same shielding logic is experimentally demonstrated - adding N-glycosylation sites to the globular head of H5 hemagglutinin (HA) allowed highly pathogenic H5N1 to escape vaccine-induced immunity (Hervé et al., Virology 2015) - but no quantitative influenza shield rules exist. Subsequent methodological and comparative work - a Bayesian machine-learning model inferring antibody-specific glycan footprints from defined site occupancies (Yu et al., 2018), integrated cryo-electron microscopy (cryo-EM), site-specific mass spectrometry, and computation to visualize the HIV shield (Berndsen et al., 2020), all-atom graph-theoretic quantification of shield vulnerability (Chakraborty et al., 2020), cross-virus glycan-density comparison across coronavirus spikes, HIV Env, Lassa glycoprotein, and influenza HA (Watanabe et al., 2020), and rapid glycan-conformer grafting tools such as GLYCO and GlycoSHIELD (Lee et al., 2022; Tsai et al., 2024) - has built components of a quantitative description without delivering rules that jointly incorporate occupancy, heterogeneity, and dynamics. Critically, a two-cohort study of 197 individuals found only limited evidence that early-infection glycan shield features predict later breadth, so even the HIV-anchored association between shield completeness and breadth remains contested (Li et al., 2021). The unresolved target is therefore twofold: the quantitative rules connecting shield chemistry and dynamics to immune escape, and the generality of the glycan-interaction taxonomy discovered for HIV-1 Env.

Problem Statement

Establish quantitative rules - explicit, predictive relationships - by which glycan occupancy (whether each potential N-linked glycosylation site is glycosylated), site-specific glycoform heterogeneity (the distribution of glycan structures at each occupied site), and glycan dynamics (the conformational motion of the glycans) jointly determine glycan-shield completeness and its immunological consequences, namely neutralization sensitivity and the development of neutralization breadth, for HIV-1 envelope glycoprotein trimers - replacing the current approximations of full occupancy and fixed spherical shielding radii, and not restricted to a single glycan site or antibody class. Because neutralization breadth develops through B-cell maturation and is only partially determined by viral features, the breadth component of this deliverable is to resolve whether shield completeness causally influences neutralization-breadth development and to quantify the glycan-shield contribution, rather than to predict breadth from viral glycan properties alone. In the same objective, determine whether the crowded-versus-dispersed glycan taxonomy defined for HIV-1 Env - a glycan being crowded when 15 or more neighboring sequons lie within a 50 Å radius - and its biological correlates (ordering, sequence conservation, glycoform processing, and antibody recognition) are conserved in the glycan shields of influenza and other enveloped viruses, including whether the Env-calibrated crowding constants remain meaningful for shields of substantially different glycan density or require density-calibrated analogs. The two deliverables serve one overarching scientific objective: a quantitative understanding of glycan-shield-mediated immune evasion, such that shield completeness, vulnerability, and escape can be predicted from glycan chemical and dynamic properties rather than measured de novo. Both deliverables are mandatory and neither alone resolves the objective: the cross-virus determination must cover, at minimum, influenza hemagglutinin (HA) plus at least one non-influenza enveloped virus (for example a coronavirus spike or the Lassa virus glycoprotein), and the HIV-1 rules must be explicit predictive relationships whose glycan-shield contribution to neutralization-breadth development is quantified rather than reported only as an association.

References

  1. Vigerust DJ, Shepherd VL (2007). Virus glycosylation: role in virulence and immune interactions. Trends in Microbiology 15:211-218. doi:10.1016/j.tim.2007.03.003, https://doi.org/10.1016/j.tim.2007.03.003
  2. Stewart-Jones GBE, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, Thomas PV, Wagh K, Zhou T, Behrens AJ, Bylund T, Choi CW, Davison JR, Georgiev IS, Joyce MG, Kwon YD, Pancera M, Taft J, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CCD, Wu CY, Bewley CA, Burton DR, Koff WC, Connors M, Crispin M, Baxa U, Korber BT, Wong CH, Mascola JR, Kwong PD (2016). Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell 165:813-826. doi:10.1016/j.cell.2016.04.010, https://doi.org/10.1016/j.cell.2016.04.010
  3. Hervé PL, Lorin V, Jouvion G, Da Costa B, Escriou N (2015). Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity. Virology 486:134-145. doi:10.1016/j.virol.2015.08.033, https://doi.org/10.1016/j.virol.2015.08.033
  4. Crispin M, Ward AB, Wilson IA (2018). Structure and Immune Recognition of the HIV Glycan Shield. Annual Review of Biophysics 47:499-523. doi:10.1146/annurev-biophys-060414-034156, https://doi.org/10.1146/annurev-biophys-060414-034156
  5. Yu WH, Zhao P, Draghi M, Arevalo C, Karsten CB, Suscovich TJ, Gunn B, Streeck H, Brass AL, Tiemeyer M, Seaman M, Mascola JR, Wells L, Lauffenburger DA, Alter G (2018). Exploiting glycan topography for computational design of Env glycoprotein antigenicity. PLoS Computational Biology 14:e1006093. doi:10.1371/journal.pcbi.1006093, https://doi.org/10.1371/journal.pcbi.1006093
  6. Wagh K, Kreider EF, Li Y, Barbian HJ, Learn GH, Giorgi E, Hraber PT, Decker TG, Smith AG, Gondim MV, Gillis L, Wandzilak J, Chuang GY, Rawi R, Cai F, Pellegrino P, Williams I, Overbaugh J, Gao F, Kwong PD, Haynes BF, Shaw GM, Borrow P, Seaman MS, Hahn BH, Korber B (2018). Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Reports 25:893-908.e7. doi:10.1016/j.celrep.2018.09.087, https://doi.org/10.1016/j.celrep.2018.09.087
  7. Berndsen ZT, Chakraborty S, Wang X, Cottrell CA, Torres JL, Diedrich JK, López CA, Yates JR 3rd, van Gils MJ, Paulson JC, Gnanakaran S, Ward AB (2020). Visualization of the HIV-1 Env glycan shield across scales. Proceedings of the National Academy of Sciences USA 117:28014-28025. doi:10.1073/pnas.2000260117, https://doi.org/10.1073/pnas.2000260117
  8. Chakraborty S, Berndsen ZT, Hengartner NW, Korber BT, Ward AB, Gnanakaran S (2020). Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail. iScience 23:101836. doi:10.1016/j.isci.2020.101836, https://doi.org/10.1016/j.isci.2020.101836
  9. Wei Q, Hargett AA, Knoppova B, Duverger A, Rawi R, Shen CH, Farney SK, Hall S, Brown R, Keele BF, Heath SL, Saag MS, Kutsch O, Chuang GY, Kwong PD, Moldoveanu Z, Raska M, Renfrow MB, Novak J (2020). Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies. iScience 23:101711. doi:10.1016/j.isci.2020.101711, https://doi.org/10.1016/j.isci.2020.101711
  10. Watanabe Y, Berndsen ZT, Raghwani J, Seabright GE, Allen JD, Pybus OG, McLellan JS, Wilson IA, Bowden TA, Ward AB, Crispin M (2020). Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nature Communications 11:2688. doi:10.1038/s41467-020-16567-0, https://doi.org/10.1038/s41467-020-16567-0
  11. Grant OC, Montgomery D, Ito K, Woods RJ (2020). Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Scientific Reports 10:14991. doi:10.1038/s41598-020-71748-7, https://doi.org/10.1038/s41598-020-71748-7
  12. Casalino L, Gaieb Z, Goldsmith JA, Hjorth CK, Dommer AC, Harbason AM, Fogarty CA, Barros EP, Taylor BC, McLellan JS, Fadda E, Amaro RE (2020). Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. ACS Central Science 6:1722-1734. doi:10.1021/acscentsci.0c01056, https://doi.org/10.1021/acscentsci.0c01056
  13. Chang D, Hackett WE, Zhong L, Wan XF, Zaia J (2020). Measuring Site-specific Glycosylation Similarity between Influenza A Virus Variants with Statistical Certainty. Molecular & Cellular Proteomics 19:1533-1545. doi:10.1074/mcp.RA120.002031, https://doi.org/10.1074/mcp.RA120.002031
  14. Li Y, Bai H, Sanders-Buell E, Dussupt V, Townsley S, Donofrio G, Bose M, O'Sullivan AM, Kibuuka H, Maganga L, Nitayaphan S, Kosgei J, Pitisuttithum P, Rerks-Ngarm S, Eller LA, Michael NL, Robb ML, Ake J, Vasan S, Tovanabutra S, Krebs SJ, Rolland M (2021). Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Journal of Virology 95:e0079721. doi:10.1128/JVI.00797-21, https://doi.org/10.1128/JVI.00797-21
  15. Lee M, Reveiz M, Rawi R, Kwong PD, Chuang GY (2022). GLYCO: a tool to quantify glycan shielding of glycosylated proteins. Bioinformatics 38:1152-1154. doi:10.1093/bioinformatics/btab791, https://doi.org/10.1093/bioinformatics/btab791
  16. Schorcht A, Cottrell CA, Pugach P, Ringe RP, Han AX, Allen JD, van den Kerkhof TLGM, Seabright GE, Schermer EE, Ketas TJ, Burger JA, van Schooten J, LaBranche CC, Ozorowski G, de Val N, Bader DLV, Schuitemaker H, Russell CA, Montefiori DC, van Gils MJ, Crispin M, Klasse PJ, Ward AB, Moore JP, Sanders RW (2022). The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. Journal of Virology 96(1):e0155221. doi:10.1128/JVI.01552-21, https://doi.org/10.1128/JVI.01552-21
  17. Allen JD, Ivory DP, Song SG, He WT, Capozzola T, Yong P, Burton DR, Andrabi R, Crispin M (2023). The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2. Cell Reports 42:112307. doi:10.1016/j.celrep.2023.112307, https://doi.org/10.1016/j.celrep.2023.112307
  18. Ringe RP, Colin P, Ozorowski G, Allen JD, Yasmeen A, Seabright GE, Lee JH, Antanasijevic A, Rantalainen K, Ketas T, Moore JP, Ward AB, Crispin M, Klasse PJ (2023). Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. PLoS Pathogens 19:e1011601. doi:10.1371/journal.ppat.1011601, https://doi.org/10.1371/journal.ppat.1011601
  19. Tsai YX, Chang NE, Reuter K, Chang HT, Yang TJ, von Bülow S, Sehrawat V, Zerrouki N, Tuffery M, Gecht M, Grothaus IL, Colombi Ciacchi L, Wang YS, Hsu MF, Khoo KH, Hummer G, Hsu SD, Hanus C, Sikora M (2024). Rapid simulation of glycoprotein structures by grafting and steric exclusion of glycan conformer libraries. Cell 187:1296-1311.e26. doi:10.1016/j.cell.2024.01.034, https://doi.org/10.1016/j.cell.2024.01.034
  20. Nawaz FZ, Adams TM, Demirturk ME, Avci FY (2026). Decoding the glycan shield: Immune recognition and response to the HIV-1 envelope trimer. Journal of Biological Chemistry 302:111350. doi:10.1016/j.jbc.2026.111350, https://doi.org/10.1016/j.jbc.2026.111350